eli lilly retatrutide phase 3 trial just announced striking results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Lilly's triple-acting obesity drug hits
Description
Combining these treatments is not contraindicated, but requires careful medical supervision, stable thyroid function, and regular monitoring
While not listed as a direct adverse effect in FDA prescribing information, this cold sensitivity appears linked to the medication's weight loss effects rather than direct temperature regulation changes
Custom Treatment Plans: The program is tailored to your weight loss goals and health needs
Research overview Retatrutide is a research peptide supplied as a lyophilised powder for laboratory research applications
